Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

    AURORA, Ontario, June 19 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP)
today announced that Dr. Heman Chao, chief scientific officer at Helix
BioPharma Corp., will be presenting a scientific poster describing L-DOS47
analytical method development findings at the 2009 American Association of
Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which
runs from June 21st to 24th at the Washington State Convention and Trade
Center in Seattle, Washington.

    The conference is a premier gathering of pharmaceutical and
biopharmaceutical scientists addressing all areas of the manufacturing,
non-clinical testing, clinical testing and regulatory treatment of established
and emerging drug compounds.

    The poster, entitled "Analytical Method Development for L-DOS47, a Novel
Candidate for the Treatment of Lung Adenocarcinoma" provides a summary of the
analytical methods which have been developed to characterize the
concentration, identity, purity, enzymatic activity, and potency of lots of
L-DOS47 drug substance and drug product.  The work presented demonstrates that
analytical methods have been successfully developed to support the
manufacture, release and subsequent stability testing of GMP batches of
L-DOS47 as Helix progresses towards initiating clinical testing with the
product.  Accompanying Dr. Chao for the poster presentation will be Dr. Juan
Davagnino, associate director, biopharmaceutical development at KBI Biopharma;
Helix's U.S.-based, third-party contract service provider responsible for
assisting Helix in developing and executing the necessary quality control and
stability testing programs for L-DOS47 drug substance and drug product lots.

    A copy of the poster is available on Helix's website for download at

    For additional information on the 2009 AAPS National Biotechnology
Conference, please visit

    About L-DOS47
    L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody, to form a potential new targeted drug
product for the treatment of adenocarcinoma of the lung, the most common form
of lung cancer in the world today. L-DOS47 is thought to function by
leveraging a natural process in the body called the urea cycle, to produce an
anti-cancer effect. It is based upon a naturally occurring enzyme called
urease that essentially reverses the urea cycle by breaking down urea into
metabolites that include ammonia and hydroxyl ions. By doing so at the site of
cancerous tissues in the body, L-DOS47 is believed to modify the
microenvironmental conditions of lung cancer cells in a manner that leads to
their death. Among these theorized effects, L-DOS47 is believed to stimulate
an increase in the pH of the microenvironment surrounding the cancerous cells,
effectively reversing the acidic extra-cellular conditions that are known to
be necessary for cancer cell survival. As well, the local production of
ammonia at the site of cancerous tissues is thought to readily diffuse into
the cancer cells to exert a potent cytotoxic effect by interfering with their
critical metabolic functions.

    About Helix BioPharma Corp.
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy.  The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies.  Helix's product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate.  Helix is listed
on the TSX under the symbol "HBP".

    For further information contact:

    Investor & Media Relations
    Ian Stone
    Russo Partners LLC
    Tel:  (619) 814-3510
    Fax:  (619) 955-5318
    Email: ian.stone@russopartnersllc.com

    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel:  (212) 845-4226
    Email: robert.flamm@russopartnersllc.com

    The reference in this news release to the AAPS website does not
constitute an endorsement by Helix of that or any other website and Helix
disclaims responsibility for the information contained in such website.  This
news release contains certain forward-looking statements and information
regarding L-DOS47, a potential cancer therapeutic under development by the
Company. Forward-looking statements and information can be identified by the
use of forward-looking terminology such as "progresses towards", "to support",
"is thought", "is believed", "new", "will", "theorized", or variations thereon
or comparable terminology referring to future events or results. Forward
looking statements and information are statements and information about the
future and are inherently uncertain, and Helix's actual results could differ
materially from those anticipated in these forward-looking statements and
information as a result of numerous factors, including without limitation,
Helix's need for additional future capital, which may not be available in a
timely manner or at all; uncertainty whether L-DOS47 will be developed
successfully as a drug or at all; research & development risks, including the
risk that early research and development results may not be repeated in later
research and development; the risk that analytical methods developed to date
may require future modification or additional methods may need to be
developed, the success of which is not assured, due to possible future changes
in the L-DOS47 formulation or manufacturing process, requirements of
regulatory authorities, or other factors; the need to further upscale the
manufacturing process for the Company's drug candidates and the risk that
further upscaling may not be achieved within the timelines expected by the
Company or at all; the need for regulatory approvals, which may not be
obtained in a timely manner or at all; the need for clinical trials, the
occurrence and success of which cannot be assured; intellectual property
risks; marketing/manufacturing risks and partnership/strategic alliance risks,
including Helix's dependency on KBI Biopharma Inc. and its other contractors,
consultants and advisors, whose performance and interdependence can critically
affect the Company's performance and the achievement of its milestones;
product liability risks; the effect of competition; the risk of technical
obsolescence; and the risk of changes in business strategy or development
plans. Such risks and uncertainties, and others affecting the Company  which
could cause actual results to vary materially from current results or those
anticipated in forward-looking statements and information, are more fully
described in the Company's latest Annual Information Form, MD&A and other
reports filed with the Canadian Securities Regulatory Authorities from time to
time at www.sedar.com, and in the Company's Form 20-F and other reports filed
with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). 
Forward-looking statements and information are based on the beliefs,
assumptions, opinions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs, assumptions,
opinions or expectations change, except as required by law.  Helix's
participation in the AAPS National Biotechnology Conference is subject to
change or cancellation without notice.


For further information:

For further information: Ian Stone, +1-619-814-3510, Fax:
+1-619-955-5318, ian.stone@russopartnersllc.com or Robert Flamm, Ph.D.,
+1-212-845-4226, robert.flamm@russopartnersllc.com, both of Russo Partners LLC
Web Site: http://www.helixbiopharma.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890